FindMyRecallSubscribe
Class I: serious health riskTerminated

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg Recall

ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · La Vergne, TN

Risk level
Class I
Reported by FDA
Jun 28, 2023
Recall ID
D-0893-2023
Check your lot numberHow we source this data

Summary

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recalled ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg starting May 31, 2023. The FDA classified it as Class I (serious health risk) and published enforcement report D-0893-2023 on Jun 28, 2023. Reason: Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg. Status: Terminated.

Why it was recalled

Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.

Product description

ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited Bachupally-500 090 India, Distributed by: Major Pharmaceuticals Livonia, MI 48152 USA, NDC 0904-6269-08

Lot numbers, UPCs & expiration codes

Lot: T04769 Exp. 2024/12

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0893-2023
Classification
Class I
Status
Terminated
Recall initiated
May 31, 2023
FDA report date
Jun 28, 2023
Quantity
unknown
Recall type
Voluntary: Firm initiated
Recalling firm
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories

Original FDA data

Every field from FDA enforcement report D-0893-2023, exactly as published.

Show all FDA fields
City
La Vergne
State
TN
Status
Terminated
Country
United States
Event ID
92463
Address
341 Mason Rd
Code information
Lot: T04769 Exp. 2024/12
Postal code
37086-3606
Report date
Jun 28, 2023
Product type
Drugs
Recall number
D-0893-2023
Classification
Class I
Recalling firm
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Product quantity
unknown
Termination date
Jul 2, 2024
Reason for recall
Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.
Voluntary / mandated
Voluntary: Firm initiated
Product description
ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited Bachupally-500 090 India, Distributed by: Major Pharmaceuticals Livonia, MI 48152 USA, NDC 0904-6269-08
Distribution pattern
Nationwide in the USA
Recall initiation date
May 31, 2023
Initial firm notification
Letter
Center classification date
Jul 5, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0893-2023, published Jun 28, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls